1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Corbus Seeking Way Forward In Systemic Sclerosis After Phase III

Results For Placebo On Par With High-Dose Lenabasum

 
• By Mandy Jackson

The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations. 

Dominoes
Lenabasum hit a roadblock in systemic sclerosis where results were similar to placebo • Source: Shutterstock

Corbus Pharmaceuticals Holdings, Inc.’s cannabinoid receptor type 2 (CB2) agonist lenabasum – the company’s only clinical-stage drug candidate – failed its first pivotal trial test, but the company is reviewing the data in hopes of finding a way forward for the drug in systemic sclerosis. Corbus said on 8 September that the similar results in the lenabasum and placebo arms of the Phase III clinical trial were due to background immunosuppressive therapy.

The Norwood, MA-based company reported top-line results on 8 September from the RESOLVE-1 trial and said its ongoing analysis of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from R&D

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.